Abstract: A pharmaceutical composition for stimulating peristaltic contraction in the intestinal canal which contains a pharmaceutically acceptable carrier or excipient and an effective amount of a polypeptide, or a salt thereof, having a pharmacological activity similar to motilin. The polypeptide has the formula B.sub.1 -Z.sub.1 -A.sub.1 -Z.sub.2 -B.sub.2 -Thr-B.sub.3 -A.sub.2 -Glu-Z.sub.3 -C-Arg-X'-Gln-Glu-Lys-Glu-Arg-D-Lys-Gly-E-Y, with Z.sub.1,Z.sub.2 and Z.sub.3 each being an amino acid residue having a hydrophobic side-chain, A.sub.1 and A.sub.2 each being an amino acid residue such as Pro, Gly, Asn and Ser, B.sub.1, B.sub.2 and B.sub.

Abstract: Vasoactive intestinal polypeptide (VIP) analogues and use thereof are disclosed. The VIP analogues are shown by the formula ofHis-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-X-Ala-Val-L ys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-Ywherein X is a residue of amino acid other than methionine (Met); and Y is homoserine, homoserine-lactone, amidized homoserine, a residue reacted homoserine-lactone with a primary alkyl amine having carbon atoms not exceeding 20, or an optional polypeptide chain and containing an amidized homoserine at C-terminal.Each of the VIP analogues is employed as an effective ingredient for various medicines and a hair tonic, and more particularly curing an asthma and impotence.

Abstract: There is disclosed a pharmaceutical preparation which contains vasoactive intestinal polypeptide (VIP), its analogue or a salt thereof, and a surfactant. The preparation shall contains further a peptidase inhibitor. The composition is administrated to suppress allergies, reduce blood pressure, increase secretion of tear, cure asthma and impotence and others.

Abstract: The invention provides a novel glycoside which contains as the aglycon a 4-(substituted phenyl)piperazine-1-yl derivative of glycyrrhetinic acid and 11-deoxo-glycyrrhetinic acid or their derivative as well as a composition for the treatment of virus infection, which contains these compounds as a main active component.

Abstract: A 3-oxygermylpropionic acid preparation is provided, which activates the action of 3-oxygermylpropionic acid having the general formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH]n wherein n=an integer of at least 1 and is readily solubilized and disintegrated in vivo. The present preparation is manufactured by compression-molding at high pressure a composition comprising 3-oxygermylpropionic acid and two or more low-molecular substance of high solubility in water. The low-molecular substances are selected from the group consisting of white sugar, sorbitol, fructose, sucrose, glucose, lactose, mannitol and sodium chloride.

Abstract: An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of 1 or 2 or more, is in the form of a white acicular or needle crystal, shows a solubility of 1.570/100 ml in water at 25.degree. C. and exhibits a melting (decomposition) point of 240.degree. C.

Abstract: A composition for inhibiting the degeneration of cells including liver cells by drugs and relieving the toxicity of drugs to internal organs including the liver contains as an essential component a 3-oxygermylpropionic acid polymer which is represented by:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 COOH].sub.nwherein n is an integer of at least 1, takes the form of a white acicular crystal and has a melting point of about 230.degree. C. at which it decomposes or coagulates. The present composition may be used with a carrier hydroxypropylcellulose in an amount of 0.005 to 50% by weight relative to 0.005 to 5% by weight of the 3-oxygermylpropionic acid polymer.

Abstract: Pharmaceutical compositions for oral administration used for the treatment and prevention of hyperlipemia, obesity and obesity-related diseases contain phytic acid or its salt as a pharmaceutically effective component.

Abstract: A pharmaceutical composition is used to treat and prevent a diabetes-dependent type of autoimmune diseases, said pharmaceutical composition comprising a therapeutically effective amount of 3-oxygermylpropionic acid represented by the following formula:[(O.sub.1/2).sub.3 GeCH.sub.2 CH.sub.2 CO.sub.2 H].sub.nwherein n stands for an integer of 1 or more, optionally with an activating carrier.

Abstract: A stabilized composition of phytic acid is obtained by the steps of:heating and drying rice bran de-fatted by pressing;adding acidic water of pH 3 to 5 to the dried rice bran, stirring the solution and completing the stirring before the pH of the solution reaches 5.7; andheating the thus obtained liquid extract to solidify protein components, followed by the removal of the solid matters by filtration. This composition is advantageously used for removing uraroma and body odor.

Abstract: Composition obtained from a rice bran, which comprises a filtrate of lactic fermented and aged material of the rice bran, the filtrate being an odorless pale yellow solution, having a salty taste, and solubility with water and alcohols, or a powderized substance of the filtrate, a process for the preparation of the composition, and use of the composition as a deodorant.

Abstract: A cloned single-strand DNA comprising nucleotide sequence which encodes an antibacterial polypeptide precursor, a cloned double-strand DNA consisting of the single-strand DNA and its complementary single-strand DNA, a DNA fragment of the single- or double-strand DNA, a process for the preparation thereof, and a plasmid, in which the double-strand DNA or its fragment is inserted.

Abstract: A stabilized phytic acid composition is provided, which comprises phytic acid or its salt and at least one stabilizer selected from the group consisting of a product obtained by the lactic fermentation and ripening of rice bran, a water-soluble polymer capable of forming a film and an additive capable of absorbing water.

Abstract: A novel composition contains phytic acid and ferric ions as main ingredients and carboxylic acid ions as a dissolution accelerator, and may further include at least one or more or two additives selected from the group consisting of a carboxylic acid or its salt, saccharides, an amino acid or its salt and an organic phosphoric acid or its salt.

Abstract: Phytic acid or at least one of its salts is used as an effective component for cell activators in a hypoxic state, circulatory ameliorators, dementia remedies and edible compositions.

Abstract: A cloned single-strand DNA comprising nucleotide sequence which encodes an antibacterial polypeptide precursor, a cloned double-strand DNA consisting of the single-strand DNA and its complementary single-strand DNA, a DNA fragment of the single- or double-strand DNA, a process for the preparation thereof, and a plasmid, in which the double-strand DNA or its fragment is inserted are disclosed.

Abstract: An organogermanium compound of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen atom, alkyl, substituted alkyl, phenyl or substituted phenyl, and R.sub.5 is a radical of ##STR2## n is an integer of 2 or more, and R.sub.6 and R.sub.7 are hydrogen atom, alkyl, substituted alkyl, phenyl or substituted phenyl,a salt of the compound, a processs for the preparation of the compound as well as a use of the compound as an affective ingredient for pharmaceutical preparations.

Abstract: A cloned single-strand DNA comprising nucleotide sequence which encodes human motilin precursor, a cloned double-strand DNA consisting of the single-strand DNA and its complementary single-strand DNA, a fragment of the single- or double-strand DNA, a plasmid, in which the double-strand DNA or its fragment is integrated, as well as a process for the preparation of the single- or double-strand DNA.

Abstract: Remedies, preventives and functional diets for diabetic diseases, esp., diabetes, contain phytic acid or its salt or salts. The salt of phytic acid is a non-toxious metal salt, or a non-toxious salt with an organic base, a basic amino acid or an organic ester residue, and has a compositional form together with or separately from phytic acid.

Abstract: Preventives or remedies for medicinal and alcoholic poisoning contain as a pharmaceutically effective component phytic acid or its salt which may be an innoxious metal salt, or an innoxious salt with an organic base, a basic amino acid or an organic ester residue.